Home    中文  
 
  • Search
  • lucene Search
  • Citation
  • Fig/Tab
  • Adv Search
Just Accepted  |  Current Issue  |  Archive  |  Featured Articles  |  Most Read  |  Most Download  |  Most Cited

Chinese Journal of Clinical Laboratory Management(Electronic Edition) ›› 2015, Vol. 03 ›› Issue (03): 160-167. doi: 10.3877.cma.j.issn.2095-5820.2015.03.006

Special Issue:

• Review • Previous Articles     Next Articles

Progress of targeted therapy for multiple myeloma

Xiaolei Chen, Wenming Chen   

  • Received:2015-07-20 Online:2015-08-28 Published:2015-08-28
  • Contact: Wenming Chen
  • About author:
    Corresponding author: Chen Wenming, Email:

Abstract:

In recent years, the treatment of multiple myeloma (MM) has progressed from the era of chemotherapy into the targeted therapy times, the targeted therapy focus on inhibiting the myeloma cell growth and survival in the bone marrow microenvironment. With the further investigation of MM, numerous novel agents and new regimens of combined chemotherapy are currently emerging. The clinical application of Immunomodulatory drugs (IMids), proteasome inhibitor based single or combined regimens has had profound effects a MM therapy, which promises for MM patients.

Key words: Multiple myeloma, Immunomodulatory drugs, Proteasome inhibitors, Monoclonal antibody

京ICP 备07035254号-20
Copyright © Chinese Journal of Clinical Laboratory Management(Electronic Edition), All Rights Reserved.
Tel: 020-81341720 Fax: 020-37103505 E-mail: clinlab@cma.org.cn
Powered by Beijing Magtech Co. Ltd